Skip to Main content Skip to Navigation
Journal articles

Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases

Jagadeesh Bayry 1 Srini Kaveri 1
1 CRC - Inserm U1138 - Immunopathologie et immunointervention thérapeutique
CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
Abstract : Neonatal Fc receptors (FcRns) recycle IgGs by preventing their lysosome degradation. As this process also enhances half-life of pathogenic auto-IgG, inspired from the mechanisms of intravenous immunoglobulin, several inhibitors of IgG-FcRn interface have been conceived for treating autoimmune diseases. Among them, the high-affinity FcRn-binding engineered Fc molecule efgartigimod has recently completed phase I clinical trial.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02455435
Contributor : Jagadeesh Bayry <>
Submitted on : Sunday, January 26, 2020 - 10:56:56 AM
Last modification on : Friday, September 18, 2020 - 2:35:04 PM

Identifiers

Citation

Jagadeesh Bayry, Srini Kaveri. Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases. Trends in Pharmacological Sciences, Elsevier, 2018, 39 (11), pp.919-922. ⟨10.1016/j.tips.2018.08.004⟩. ⟨inserm-02455435⟩

Share

Metrics

Record views

293